Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice

Journal of Immunology

Volumn 178, Issue 7, 2007, Pages 4194-4213

  Niu, Liguo ^a   Strahotin, Simona ^a   Hewes, Becker ^a   Zhang, Benyue ^a   Zhang, Yuanyuan ^a   Archer, David ^a   Spencer, Trent ^a   Dillehay, Dirck ^a   Kwon, Byoung ^c   Chen, Lieping ^b   Vella, Anthony T ^d   Mittler, Robert S ^a,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Ulsan   (South Korea)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BROXURIDINE; CD137 ANTIGEN; CD19 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FAS ANTIGEN; GAMMA INTERFERON; HEMOGLOBIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HEPATOMEGALY; HUMORAL IMMUNITY; LYMPHADENOPATHY; LYMPHOCYTE MIGRATION; LYMPHOCYTE TRAFFICKING; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RETICULOCYTE; SINGLE DRUG DOSE; SPLENOMEGALY; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 33947696816     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.7.4194     Document Type: Article

References (73)

1. Watts, T. H, 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68.
2. Melero, I., W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellstrom, R. S. Mittler, and L. Chen. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3: 682-685.
3. Melero, I., N. Bach, K. E. Hellstrom, A. Aruffo, R. S. Mittler, and L. Chen. 1998. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-IBB ligand: synergy with the CD28 costimulatory pathway. Eur. J. Immunol. 28: 1116-1121.
4. + T cells. Am. J. Transplant. 3: 543-551.
5. 1 mice. J. Clin. Invest. 111: 1505-1518.
6. Foell, J. L., B. I. Diez-Mendiondo, O. H. Diez, U. Holzer, P. Ruck, A. S. Bapat, M. K. Hoffmann, R. S. Mittler, and G. E. Dannecker. 2004. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 113: 89-98.
7. Sun, Y., H. M. Chen, S. K. Subudhi, J. Chen, R. Koka, L. Chen, and Y. X. Fu. 2002. Costimulatory molecule-targeted antibody therapy of a spontaneous auto-immune disease. Nat. Med. 8: 1405-1413.
8. Seo, S. K., J. H. Choi, Y. H. Kim, W. J. Kang, H. Y. Park, J. H. Suh, B. K. Choi, D. S. Vinay, and B. S. Kwon. 2004. 4-lBB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10: 1088-1094.
9. + T cell responses. Nat. Immunol. 3: 536-541.
10. Tan, J. T., J. K. Whitmire, K. Murali-Krishna, R. Ahmed, J. D. Altman, R. S. Mittler, A. Sette, T. C. Pearson, and C. P. Larsen. 2000. 4-IBB costimulation is required for protective anti-viral immunity after peptide vaccination. J. Immunol. 164: 2320-2325.
11. Bukczynski, J., T. Wen, K. Ellefsen, J. Gauldie, and T. H. Watts. 2004. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses, Proc. Natl. Acad. Sci. USA 101: 1291-1296.
12. Bukczynski, J., T. Wen, C. Wang, N. Christie, J. P. Routy, M. R. Boulassel, C. M. Kovacs, K. S. Macdonald, M. Ostrowski, R. P. Sekaly, et al. 2005. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J. Immunol. 175: 6378-6389.
13. Tacke, M., G. Hanke, T. Hanke, and T. Hunig. 1997. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27: 239-247.
14. Luhder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Muller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, and T. Hunig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 955-966.
15. Wadman, M. 2006. London's disastrous drug trial has serious side effects for research. Nature 440: 388-389.
16. Marshall, E. 2006. Drug trials: violent reaction to monoclonal antibody therapy remains a mystery. Science 311: 1688-1689.
17. Pollok, K. E., Y. J. Kim, Z. Zhou, J. Hurtado, K. K. Kim, R. T. Pickard, and B. S. Kwon. 1993. Inducible T cell antigen 4-1BB: analysis of expression and function. J. Immunol. 150: 771-781.
18. Melero, I., J. V. Johnston, W. W. Shufford, R. S. Mittler, and L. Chen. 1998. NK1.1 cells express 4-1BB (CDwl37) costimulatory molecule and are required for tumor immunity elicited by anti-4-lBB monoclonal antibodies. Cell. Immunol. 190: 167-172.
19. Wilcox, R. A., A. I. Chapoval, K. S. Gorski, M. Otsuji, T. Shin, D. B. Flies, K. Tamada, R. S. Mittler, H. Tsuchiya, D. M. Pardoll, and L. Chen. 2002. Cutting edge: expression of functional CD137 receptor by dendritic cells. J. Immunol. 168: 4262-4267.
20. Futagawa, T., H. Akiba, T. Kodama, K. Takeda, Y. Hosoda, H. Yagita, and K. Okumura. 2002. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14: 275-286.
21. Heinisch, I. V., I. Daigle, B, Knopfli, and H. U. Simon. 2000. CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils. Eur. J. Immunol. 30: 3441-3446.
22. Schwarz, H., J. Valbracht, J. Tuckwell, J. von Kempis, and M. Lotz. 1995. ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 85: 1043-1052.
23. Heinisch, I. V., C. Bizer, W. Volgger, and H. U. Simon. 2001. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J. Allergy Clin. Immunol. 108: 21-28.
24. Reali, C., M. Curto, V. Sogos, F. Scintu, S. Pauly, H. Schwarz, and F. Gremo. 2003. Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2. J. Neurosci. Res. 74: 67-73.
25. Nishimoto, H., S. W. Lee, H. Hong, K. G. Potter, M. Maeda-Yamamoto, T. Kinoshita. Y. Kawakami, R. S. Mittler, B. S. Kwon, C. F. Ware, et al. 2005. Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood 106: 4241-4248.
26. Broll, K., G. Richter, S. Pauly, F. Hofstaedter, and H. Schwarz. 2001. CD137 expression in tumor vessel walls: high correlation with malignant tumors. Am. J. Clin. Pathol. 115: 543-549.
27. Takahashi, C., R. S. Mittler, and A. T. Vella, 1999. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162: 5037-5040.
28. L and Bfl-1. J. Immunol. 169: 4882-4888.
29. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186: 47-55.
30. Mittler, R, S., T. S. Bailey, K. Klussman, M. D. Trailsmith, and M. K. Hoffmann. 1999. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J. Exp. Med. 190: 1535-1540.
31. + regulatory T cells. J. Immunol. 173: 2428-2434.
32. + T cells. J. Leukocyte Biol. 75: 785-791.
33. + cytolytic T lymphocytes in vivo. Blood 103: 177-184.
34. Myers, L., C. Takahashi, R. S. Mittler, R. J. Rossi. and A. T. Vella. 2003. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc. Natl. Acad Sci. USA 100: 5348-5353.
35. Myers, L., M. Croft, B. S. Kwon, R. S. Mittler, and A. T. Vella. 2005. Peptide-specific CD8 T regulatory cells use IFN-γ to elaborate TGF-β-based suppression. J. Immunol. 174: 7625-7632.
36. Kwon, B. S., J. C. Hurtado, Z. H. Lee, K. B. Kwack, S. K. Seo, B. K. Choi, B. H. Koller, G. Wolisi, H. E. Broxmeyer, and D. S. Vinay. 2002. Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. 168: 5483-5490.
37. Loo, D. T., N. J. Chalupny, J. Bajorath, W. W. Shuford, R. S. Mittler, and A. Aruffo. 1997. Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB. J. Biol. Chem. 272: 6448-6456.
38. Shiow, L. R., D. B. Rosen, N. Brdickova, Y. Xu, J. An, L. L. Lanier, J. G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon- αβ to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440: 540-544.
39. Vosshenrich, C. A., M. E. Garcia-Ojeda, S. I. Samson-Villeger, V. Pasqualetto, L. Enault, O. R. Goff, E. Corcuff, D. Guy-Grand, B. Rocha, A. Cumano, et al. 2006. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat. Immunol. 7: 1217-1224.
40. - surface phenotype and the α, β heterodimer of the T cell antigen receptor. J. Immunol. 143: 1118-1122.
41. Young, K. J., B. DuTemple, M. J. Phillips, and L. Zhang. 2003. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J. Immunol. 171: 134-141.
42. - T cell receptor αβ T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection. J. Exp. Med. 174: 193-201.
43. + T cells in murine cytomegalovirus infection. Immunology 101: 19-29.
44. Gutierrez-Ramos, J. C., J. L. Andreu, Y. Revilla, E. Vinuela, and C. Martinez. 1990. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 346: 271-274.
45. Rogers, J. A., and J. W. Berman. 1994. TNF-α inhibits the further development of committed progenitors while stimulating multipotential progenitors in mouse long-term bone marrow cultures. J. Immunol. 153: 4694-4703.
46. Jacobsen, S. E., F. W. Jacobsen, C. Fahlman, and L. S. Rusten. 1994. TNF-α, the great imitator: role of p55 and p75 TNF receptors in hematopoiesis. Stem Cells 12(Suppl. 1): 111-126.
47. + human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85: 3183-3190.
48. Oyaizu, N., T. W. McCloskey, S. Than, R. Hu, V. S. Kalyanaraman, and S. Pahwa. 1994. Cross-linking of CD4 molecules up-regulates Fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion. Blood 84: 2622-2631.
49. Garvy, B. A., J. M. Elia, B. L. Hamilton, and R. L. Riley. 1993. Suppression of B-cell development as a result of selective expansion of donor T cells during the minor H antigen graft-versus-host reaction. Blood 82: 2758-2766.
50. Tacchini-Cottier, F., C. Vesin, M. Redard, W. Buurman, and P. F. Piguet. 1998. Role of TNFRl and TNFR2 in TNF-induced platelet consumption in mice. J. Immunol. 160: 6182-6186.
51. Senaldi, G., and P. F. Piguet. 1998. Mortality and platelet depletion occur independently of fibrinogen consumption in murine models of tumor necrosis factor-mediated systemic inflammatory responses. Cytokine 10: 382-389.
52. Yatomi, Y., F. Ruan, S. Hakomori, and Y. Igarashi. 1995. Sphingosine-1-phos-phate: a platelet-activating sphingolipid released from agonist stimulated human platelets. Blood 86: 193-202.
53. Yatomi, Y., Y. Igarashi, L. Yang, N. Hisano, R. Qi, N. Asazuma, K. Satoh, Y. Ozaki, and S. Kume. 1997. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J. Biochem. 121: 969-973.
54. Igarashi, Y., and Y. Yatomi. 1998. Sphingosine 1-phosphate is a blood constituent released from activated platelets, possibly playing a variety of physiological and pathophysiological roles. Acta Biochim. Pol. 45: 299-309.
55. Matloubian, M., C. G. Lo, G. Cinamon, M. J. Lesneski, Y. Xu, V. Brinkmann, M. L. Allende, R. L. Proia, and J. G. Cyster. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360.
56. Degre, M. 1973. Influence of polyinosinic:polycytidylic acid on the circulating white blood cells in mice. Proc. Soc. Exp. Biol. Med. 142: 1087-1091.
57. Korngold, R., K. J. Blank, and D. M. Murasko. 1983. Effect of Interferon on thoracic duct lymphocyte output: induction with either poly I:poly C or vaccinia virus. J. Immunol. 130: 2236-2240.
58. Young, A. J., T. J. Seabrook, W. L. Marston, L. Dudler, and J. B. Hay. 2000. A role for lymphatic endothelium in the sequestration of recirculating γδ T cells in TNF-α-stimulated lymph nodes. Eur. J. Immunol. 30: 327-334.
59. Theofilopoulos, A. N., R. Baccala, B. Beutler, and D. H. Kono. 2005. Type I interferons (αβ) in immunity and autoimmunity. Annu. Rev. Immunol. 23: 307-336.
60. Jo, M., T. H. Kim, D. W. Seol, J. E. Esplen, K. Dorko, T. R. Billiar, and S. C. Strom. 2000. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6: 564-567.
61. Zheng, S. J., P. Wang, G. Tsabary, and Y. H. Chen. 2004. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 113: 58-64.
62. Lacronique, V., A. Mignon, M. Fabre, B. Viollet, N. Rouquet, T. Molina, A. Porteu, A. Henrion, D. Bouscary, P. Varlet, et al. 1996. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2: 80-86.
63. Redondo, C., I. Flores, A. Gonzalez, S. Nagata, A. C. Carrera, I. Merida, and A. C. Martinez. 1996. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. J. Clin. Invest. 98: 1245-1252.
64. Tesselaar, K., R. Arens, G. M. van Schijndel, P. A. Baars, M. A. van der Valk, J. Borst, M. H. van Oers, and R. A. van Lier. 2003. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat. Immunol. 4: 49-54.
65. Spriggs, D. R., M. L. Sherman, E. Frei III, and D. W. Kufe. 1987. Clinical studies with tumor necrosis factor. Ciba Found. Symp. 131: 206-227.
66. Lehmann, V., M. A. Freudenberg, and C. Galanos. 1987. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine- treated mice. J. Exp. Med. 165: 657-663.
67. Leist, M., F. Gantner, S. Jilg, and A. Wendel. 1995. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J. Immunol. 154: 1307-1316.
68. Aman, M. J., U. Keller, G. Derigs, M. Mohamadzadeh, C. Huber, and C. Peschel. 1994. Regulation of cytokine expression by interferon-α in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 84: 4142-4150.
69. Lin, Q., C. Dong, and M. D. Cooper. 1998. Impairment of T and B cell development by treatment with a type I Interferon. J. Exp. Med. 187: 79-87.
70. Deonarain, R., A. Verma, A. C. Porter, D. R. Gewert, L. C. Platanias, and E. N. Fish. 2003. Critical roles for IFN-β in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor α. Proc. Natl. Acad. Sci. USA 100: 13453-13458.
71. + hematopoietic stem cells. Leukemia 16: 1135-1142.
72. Sangfelt, O., S. Erickson, S. Einhorn, and D. Grander. 1997. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 14: 415-423.
73. Zhu, G., D. B. Flies, K. Tamada, Y. Sun, M. Rodriguez, Y. X. Fu, and L. Chen. 2001. Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Eα-transgenic mice. J. Immunol. 167: 2671-2676.